Brought to you by 
Mitsubishi Tanabe gets Japanese rights to Invossa from Kolon
20 Dec 2017
Executive Summary
In the largest single-territory deal by a South Korean biopharma company, Kolon Life Science Inc. licensed Mitsubishi Tanabe Pharma Corp. exclusive rights to develop and commercialize the osteoarthritis gene therapy Invossa in Japan.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com